This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.31, moving +1.54% from the previous trading session.
Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold
by Zacks Equity Research
With the FDA's clinical hold, no new studies can be initiated on Merck's (MRK) islatravir. While six studies on islatravir have been placed on full clinical hold, seven have been put on partial clinical hold.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $70.25, moving -0.07% from the previous trading session.
Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies
by Zacks Equity Research
Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.
Amazon's (AMZN) AWS Gets Selected by Gilead, Boosts Clientele
by Zacks Equity Research
Amazon's (AMZN) AWS is chosen by Gilead Sciences as the preferred cloud provider.
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
Top Analyst Reports for Accenture, Raytheon & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corporation (RTX), and Becton, Dickinson, and Company (BDX).
Ligand's (LGND) Drug-Developing Technologies Holds Potential
by Zacks Equity Research
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
by Zacks Equity Research
Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
by Zacks Equity Research
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.
Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy
by Zacks Equity Research
The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.
Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus
by Zacks Equity Research
Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.
Gilead (GILD) Exercises Options to Three Arcus Programs
by Zacks Equity Research
Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb
by Zacks Equity Research
Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.
Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.
Markets Close at or Near Record Highs; Sales Misses for AAPL, AMZN, SBUX
by Mark Vickery
Most of these economic metrics and earnings reports are a peek in the rearview mirror; the real news is ahead of us.
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 54.07% and 19.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.